Current as of: March 4, 2014
Name: Justin Frank Doan
Contact Information:
Email:
Cell: 203-430-8636
Address: 22 Padens Court, Wallingford, CT 06492
Work Experience / Current Job TitleAugust 2011- Present
Associate Director
Bristol-Myers Squibb
Responsible for developing global health economics strategy for a novel oncology product. Primary duties include interfacing with global partners in order to ensure that all global affiliates have the data that they need in order to submit country specific information necessary for global reimbursement agencies to make coverage decisions for BMS products. Additional duties includes executing and overseeing health economics tactics such as developing cost effectiveness models, budget impact models, retrospective database analyses, and global value dossiers.
Job Title
May 2011-September 2011
Principal Health Economist
Genentech, Inc.
Duties include developing health economic strategies in support of blockbuster product launch preparation. Responsible for working with various Genentech partners and external thought leaders on ensuring optimal value proposition work to support the US market. Conducted multiple projects involving payer evidence planning to ensure that health economics tactics would resonate and provide adequate evidence for making coverage decisions. Other responsibilities include managing the lifecycle of a marketed product for breast and gastric cancer and leading a cross-functional market access team.
Job Title
September 2008-April 2011
Sr. Health Economist
Genentech, Inc.
Duties include developing health economic strategies in early development and interfacing with the appropriate internal stakeholders to ensure cross-functional strategic and tactical alignment. Responsible for the execution of tactics to support brand strategy and maintain responsibility of a product from development through patent expiration. Involved in Phase II, Phase III, and Phase IV health economic activities.
Job Title
April 2007-September 2008
Sr. Pharmacoeconomic Scientist
Takeda Global Research and Development, Deerfield, IL
Duties include conducing pharmacoecnomic studies including cost benefit anlaysis, cost of illness, cost utility analysis, and mathematical modeling. In addition to conducing various ad-hoc analysis, I am currently responsible for managing approximately 15-20 different projects all of which are outcomes oriented. In this role, I additionally interacted with global counterparts at Takeda in order to provide an efficient and common global health economics strategy to support products in development.
Job Title
September 2005- April 2007
Pharmacoeconomic Scientist
Takeda Pharmaceuticals North America, Deerfield, IL
Duties include managing health economic projects in support of various marketed products. Primary responsibilities were developing protocols for outcomes related databases studies, development of base case simulation models, and managing publication activities to support my managed markets colleagues in order to facilitate dialogue with managed care customers. In order to successfully complete the aforementioned duties, I was actively involved with various cross-functional teams including managed markets, medical, publications, new product planning, and the field force.
Job Title
May 2004-September 2005
Applied Health Outcomes - Palm Harbor, FL
Research Consultant
Duties include conducting systematic reviews of literature on a variety of health conditions including diabetes, HIV, cerebrovascular disease, postoperative ileus, hypertension, and heart disease. These reviews were primarily focused on the economic impact of the introduction of novel pharmaceuticals or medical devices on the health care market. Projective modeling and predictive analyses were conducted to determine the degree to which these novel interventions would impact the health care market and the organizations responsible for their development.
Job Title
January 2004-May 2004
Applied Health Outcomes - Palm Harbor, FL
Health Outcomes Intern
Duties included working with senior outcomes research professional to develop clear and concise research investigations. Our overall objectives were to plan, develop and execute managed markets and outcomes research strategies for pharmaceutical and medical intervention organizations. I not only built upon my existing knowledge about medical interventions but additionally learned about the economics involved in the health care industry through Markov analyses, cost-benefit analyses, and consumer satisfaction indices.
Job Title
December 2003- June 2004
Columbia University and the Florida Mental Health Institute - Tampa, FL
Project Coordinator-Columbia University TeenScreen Program
The project is a collaborative effort with Columbia University to implement the TeenScreen program, a screening program that identifies and connects children suffering from mental illness to the appropriate treatment services. Coordinated and led group meetings, presented the program to various community agencies, scheduled and conducted TeenScreen training, prepared all materials (consent forms, follow-up forms, and screening forms), collected and prepared data for input and analysis, and organized all activities and necessary materials for the screening process.
Education /
· University of Florida, Gainesville, FL
Bachelor of Science Degree in Psychology, May, 2001· University of South Florida, Tampa, FL
Master’s of Public Health: Epidemiology and Biostatistics, July, 2004
Professional Affiliations / · International Society for Pharmacoeconomics and Outcomes Research, September 2005-Present
· American Society of Clinical Oncology
November 2008- Present
· American Managed Care Pharmacy
July 2007- Present
Certifications / · Visiting faculty in Research, University of South Florida
· ISPOR ePRO committee member
· ISPOR CEA committee member
· ISPOR Oncology committee member
Publications Conference Presentations / Poster and Podium Presentations:
· Assessment of Burden of Illness in Women with HER2+ Metastatic Breast Cancer: Findings from a Community Web-Based Survey. Presented: European Society for Medical Oncology (ESMO) 2011.
· Health Resource Utilization and Costs Associated with Gastric Cancer: Results from a US Claims Database. Presented: European Society for Medical Oncology (ESMO) 2011.
· Symptom Burden Declines when Breast Cancer Patients Treated with Adjuvant Trastuzumab/Combination Chemotherapy Regimens Enter Trastuzumab Monotherapy Follow-up. Presented: San Antonio Breast Cancer Symposium 2010.
· HER2 Status and Trastuzumab Use Among Patients with Early Breast Cancer Receiving Care within the US Oncology Network. Presented: European Society for Medical Oncology (ESMO) 2010.
· The Role of Patient Selection Criteria in Identifying Ovarian Cancer Patients in a Retrospective Database Analysis. EuroISPOR 2010.
· Patters of care and Outcomes following Disease Progression Among Adjuvant Breast Cancer Patients Treated with Trastuzumab in the Community Setting. Presented: ASCO Annual Conference 2010.
· Impact of CNS metastases on Treatment and Survival in Elderly Patients Receiving Trastuzumab for Metastatic Breast Cancer (MBC). Presented: ASCO Annual Conference 2010.
· The Economic Burden of Ovarian Cancer in a United States Managed Care Database. Presented: Society for Gynecologic Cancer 2010.
· Cost of Care for Medicare Patients Diagnosed with Metastatic Breast Cancer Who Received Trastuzumab. Presented: ISPOR 2009.
· Trastuzumab Use and CNS Metastasis in Medicare Patients Diagnosed with Metastatic Breast Cancer. Presented ASCO 2009.
· Trastuzumab Use in Medicare Patients Diagnosed with Metastatic Breast Cancer (MBC). Presented: Miami Breast Cancer Conference (2009).
· Cost of Care for Medicare Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab. Accepted: International Society for Pharmacoeconomics and Outcomes Research (2009).
· Indirect Costs Associated with Patients Treated for Insomnia: An Employer Perspective. American College of Clinical Pharmacy (2008).
· Long-Term Treatment with Benzodiazepine Receptor Agonists: Focus on Older Adults. American Geriatrics Society (2008).
· Cost of Insomnia in the UK. European Sleep Research Society (2008).
· Patient Satisfaction in Insomnia: Development of a Psychometric Based Assessment. European Sleep Research Society (2008).
· Duration of Benzodiazepine Receptor Agonist Use for the Treatment of Insomnia. American Association for Nurse Practitioners (2008).
· Substance Abuse Among Insomnia Patients Taking a Nonbenzodiazepine Receptor Agonist, Benzodiazepine, or Melatonin Receptor Agonist. European Sleep Research Society (2008).
· Risk of Accidents in Older Adults Taking Medications for Insomnia. American Association for Geriatric Psychiatry (2008).
· Substance Abuse among Patients Diagnosed with Insomnia. International Society for Pharmacoeconomics and Outcomes Research (2008).
· The Development of a Patient Satisfaction Instrument for Insomnia: A Psychometric Approach. International Society for Pharmacoeconomics and Outcomes Research (2008).
· Long-term use of Benzodiazepine Receptor Agonists. American Society of Health-Care Pharmacists (2007).
· Effects of Insomnia on Quality of Life, Work Productivity, and Activity Impairment. International Society for Quality of Life Research (2007).
· Insomnia Medication Use in an Elderly Population and the Risk of an Accidental Event. American Society of Health-Care Pharmacists (2007).
· Healthcare Cost Comparisons by Point-of-Service for Employees with or without Insomnia. Academy of Managed Care Pharmacy (2007).
· Assessment of Work Absences Associated with Insomnia. Academy of Managed Care Pharmacy (2007).
· Cost of Illness for Insomnia: Medical, Pharmacy, and Work Absence Costs in Employees With or Without Insomnia. Associated Professional Sleep Societies (2007).
· Objective Costs and Prevalence of Comorbidities during the Year Following Diagnosis for Persons with and without Insomnia. European ISPOR (2007).
Manuscripts:
· Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer. J Cancer Epidemiol. 2012;2012:819210.
· Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab. Griffiths RI, Lalla D, Herbert RJ, Doan JF, Brammer MG, Danese MD. Cancer Invest. 2011 Nov; 29(9):573-84.
· Assessing the reliability and validity of a newly developed insomnia treatment satisfaction questionnaire (ITSAT-Q). Beyer AP, Szeinbach SL, Seoane-Vazquez EC, Gliem JA, Doan J, Wal GS, Lichstein KL.Sleep Med. 2010 Sep;11(8):766-71.
· Insomnia medication use and the probability of an accidental event in an older adult population. Avidan AY, Palmer LA, Doan JF, Baran RW. Drug Healthc Patient Saf. 2010;2:225-32. Epub 2010 Sep 28.
· Health benefit costs and absenteeism due to insomnia from the employer's perspective: a retrospective, case-control, database study. Kleinman NL, Brook RA, Doan JF, Melkonian AK, Baran RW.J Clin Psychiatry. 2009 Aug;70(8):1098-104.
· Association of insomnia with quality of life, work productivity, and activity impairment. Bolge SC, Doan JF, Kannan H, Baran RW. Qual Life Res. 2009 May;18(4):415-22. Epub 2009 Mar 14.
Relevant Coursework / · UK Secondment Takeda Pharmaceuticals Global Research and Development (mentorship in UK affiliate)
· Advanced Modeling Methods for Health Economic Evaluation. University of York- Center for Health Economics (2008).
· Advanced Training Program- Pharmacoeconomics, the next generation. University of Arizona: Center for Health Outcomes & Pharmaceconomic Research (2007).
· Training Program in Health Outcomes and Pharmacoeconomics Research. University of Arizona: Center for Health Outcomes & Pharmaceconomic Research (2006).
Page 1 of 5
Curriculum Vitae